In a recent phase 3 trial, intravenous anrikefon demonstrated significant benefits for patients with chronic kidney disease-associated pruritus undergoing hemodialysis. Over 12 weeks, 37% of participants receiving anrikefon achieved at least a 4-point reduction in itch severity, compared to 15% in the placebo group. Quality of life improvements were also noted, especially within the 5-D Itch scale. While some adverse events were observed, including dizziness and a total of 20 deaths, the overall findings suggest anrikefon is a promising candidate for treating this condition. These results were published in The BMJ.

Source: The BMJ